China Approves New Clinical Trial Targeting Advanced Colorectal Cancer

Nanjing, Monday, 3 August 2026.
China approved Nanjing Leads Biolabs to begin clinical trials for a novel therapy targeting advanced colorectal cancer, offering hope to the 95% of patients resistant to current immunotherapies.